Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
Rekrutierend
NCT-Nummer:
NCT03897127
Studienbeginn:
September 2019
Letztes Update:
18.11.2023
Wirkstoff:
Cytarabine, Daunorubicin, CPX-351
Indikation (Clinical Trials):
Leukemia, Myeloid, Leukemia, Myeloid, Acute
Geschlecht:
Alle
Altersgruppe:
Erwachsene (18+)
Phase:
Phase 3
Sponsor:
University of Ulm
Collaborator:
Jazz Pharmaceuticals
Kontakt
Verena Gaidzik, MD Kontakt: Phone: 0049-731-500 Phone (ext.): 45707 E-Mail: verena.gaidzik@uniklinik-ulm.de» Kontaktdaten anzeigen
Studienlocations (3 von 64)
Graz Austria Innsbruck Linz Rankweil Salzburg Wien Aschaffenburg Deutschland Bad Saarow Brandenburg Germany Berlin Bochum Nordrhein-Westfalen Bonn Braunschweig Niedersachsen Bremen Darmstadt Hessen Dortmund Düsseldorf Essen Esslingen am Neckar Baden-Württemberg Flensburg Schleswig-Holstein Freiburg Gießen Goch Greifswald Mecklenburg-Vorpommern Hamburg Hamm Hannover Heilbronn Herne Kaiserslautern Rheinland-Pfalz Karlsruhe Lemgo Ludwigshafen Lübeck Lüdenscheid Magdeburg Sachsen-Anhalt Mainz Meschede Minden München Bayern Offenbach am Main Offenburg Oldenburg Passau Regensburg Saarlouis Saarland Sande Stuttgart Traunstein Trier Tübingen Ulm Villingen-Schwenningen Wuppertal
Brustzentrum am Klinikum Aschaffenburg 63739 Aschaffenburg DeutschlandRekrutierend » Google-Maps Ansprechpartner: Manfred Welslau, MD Simone Liebler, MD » Ansprechpartner anzeigen Helios Klinikum Bad Saarow 15526 Bad Saarow (Brandenburg) GermanyRekrutierend » Google-Maps Ansprechpartner: Daniel Schöndube, MD Richard Ratai, MD » Ansprechpartner anzeigen Berlin Charite - Campus Charite Mitte 10117 Berlin (Berlin) GermanyRekrutierend » Google-Maps Ansprechpartner: Jörg Westermann, MD Philipp Le Coutre, MD » Ansprechpartner anzeigen Vivantes Klinikum Am Urban 10967 Berlin (Berlin) GermanyRekrutierend » Google-Maps Ansprechpartner: Christian Scholz, MD Annette Dieing, MD » Ansprechpartner anzeigen Berlin Charite - Campus Benjamin Franklin 12200 Berlin (Berlin) GermanyRekrutierend » Google-Maps Ansprechpartner: Jörg Westermann, MD Jan Krönke, MD » Ansprechpartner anzeigen Vivantes Klinikum Neukölln 12351 Berlin (Berlin) GermanyRekrutierend » Google-Maps Ansprechpartner: Maike de Witt, MD Lore Marretta, MD » Ansprechpartner anzeigen Charité Berlin 13353 Berlin (Berlin) GermanyRekrutierend » Google-Maps Ansprechpartner: Jörg Westermann, MD Anne Flörcken, MD » Ansprechpartner anzeigen Bochum, Augusta-Kranken-Anstalt 44791 Bochum (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Stefan Lukic, MD Robert Radkowski, MD » Ansprechpartner anzeigen Knappschaftskrankenhaus Bochum-Langendreer 44892 Bochum (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Roland Schroers, MD Deepak Ben Vangala, MD » Ansprechpartner anzeigen Universitätsklinikum Bonn 53105 Bonn (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Teichmann Lino, MD Katjana S Schwab, MD » Ansprechpartner anzeigen Städtisches Klinikum Braunschweig gGmbH 38114 Braunschweig (Niedersachsen) GermanyRekrutierend » Google-Maps Ansprechpartner: Jürgen Krauter, MD Carsten Springer, MD » Ansprechpartner anzeigen Klinikum Bremen-Mitte 28177 Bremen (Bremen) GermanyRekrutierend » Google-Maps Ansprechpartner: Bernd Hertenstein, MD Stephan Kaun, MD » Ansprechpartner anzeigen Klinikum Darmstadt 64283 Darmstadt (Hessen) GermanyRekrutierend » Google-Maps Ansprechpartner: Helga Bernhard, MD Stephan Schäfer, MD » Ansprechpartner anzeigen St.-Johannes-Hospital 44137 Dortmund (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Darina Kodzhabasheva, MD Ralf Georg Meyer, MD » Ansprechpartner anzeigen Darmkrebszentrum Universitätsklinikum Düsseldorf Moorenstraße 5 40225 Düsseldorf DeutschlandRekrutierend » Google-Maps Ansprechpartner: Ulrich Germing, MD Kathrin Nachtkamp, MD » Ansprechpartner anzeigen Kliniken Essen Süd, Ev. Krankenhaus Essen- Werden gGmbH 45239 Essen (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Stephanie von Harsdorf, MD Peter Reimer, MD » Ansprechpartner anzeigen Interdisziplinäres Brustzentrum am Klinikum Esslingen Hirschlandstraße 97 73730 Esslingen am Neckar (Baden-Württemberg) DeutschlandRekrutierend » Google-Maps Ansprechpartner: Swen Wessendorf, MD Guido Hausner, MD » Ansprechpartner anzeigen Malteser Krankenhaus St. Franziskus-Hospital 24939 Flensburg (Schleswig-Holstein) GermanyRekrutierend » Google-Maps Ansprechpartner: Angela Krackhardt, MD Milena Milovanovic, MD » Ansprechpartner anzeigen Universitätsklinikum Freiburg 79106 Freiburg (Baden-Württemberg) GermanyRekrutierend » Google-Maps Ansprechpartner: Michael Lübbert, MD Ralph Wäsch, MD » Ansprechpartner anzeigen Magenkrebszentrum am Universitätsklinikum Gießen Schubertstraße 81 35392 Gießen DeutschlandRekrutierend » Google-Maps Ansprechpartner: Maisun Abu Samra, MD Mathias Rummel, MD » Ansprechpartner anzeigen Katholisches Karl-Leisner-Klinikum gGmbH, Wilhelm-Anton-Hospital gGmbH Goch 47574 Goch (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Volker Runde, MD Jörn Westheider, MD » Ansprechpartner anzeigen Interdisziplinäres Brustzentrum der Universitätsmedizin Greifswald Ferdinand-Sauerbruch-Straße 17475 Greifswald Greifswald (Mecklenburg-Vorpommern) DeutschlandRekrutierend » Google-Maps Ansprechpartner: Claudia Moskwa, MD Christian Späth, MD » Ansprechpartner anzeigen Asklepios Kliniken Hamburg GmbH St. Georg 20099 Hamburg (Hamburg) GermanyRekrutierend » Google-Maps Ansprechpartner: Ahmet Elmaagacli, MD Anju Singh, MD » Ansprechpartner anzeigen Brustzentrum am Universitätsklinikum Hamburg-Eppendorf Martinistraße 52 20251 Hamburg DeutschlandRekrutierend » Google-Maps Ansprechpartner: Walter Fiedler, MD Winfried H Alsdorf, MD » Ansprechpartner anzeigen Asklepios Klinik Altona 22763 Hamburg (Hamburg) GermanyRekrutierend » Google-Maps Ansprechpartner: Hans Salwender, MD Johanna Wilmsen, MD » Ansprechpartner anzeigen Evangelisches Krankenhaus Hamm gGmbH 59063 Hamm (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Alexander Baraniskin, MD Andrea Stoltefuß, MD » Ansprechpartner anzeigen Klinikum Region Hannover - Klinikum Siloah 30459 Hannover (Niedersachsen) GermanyRekrutierend » Google-Maps Ansprechpartner: Daniela Dörfel, MD Martin Müller, MD » Ansprechpartner anzeigen Leberkrebszentrum Medizinische Hochschule Hannover Carl-Neuberg-Straße 1 30625 Hannover DeutschlandRekrutierend » Google-Maps Ansprechpartner: Felicitas Thol, MD Michael Heuser, MD » Ansprechpartner anzeigen SLK-Kliniken GmbH Heilbronn 74078 Heilbronn (Baden-Württemberg) GermanyRekrutierend » Google-Maps Ansprechpartner: Markus Lindauer, MD Uwe Martens, MD » Ansprechpartner anzeigen Marienhospital Herne, Klinikum der Ruhr 44625 Herne (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Dirk Strumberg, MD Marta Litter, MD » Ansprechpartner anzeigen Kaiserslautern, Westpfalz-Klinikum 67655 Kaiserslautern (Rheinland-Pfalz) GermanyRekrutierend » Google-Maps Ansprechpartner: Gerhard Held, MD Milena Pfeifer, MD » Ansprechpartner anzeigen Städtisches Klinikum Karlsruhe gGmbH 76133 Karlsruhe (Baden-Württemberg) GermanyRekrutierend » Google-Maps Ansprechpartner: Mark Ringhoffer, MD Lukas Kündgen, MD » Ansprechpartner anzeigen Klinikum Lippe-Lemgo 32657 Lemgo (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Breuch Philipp, MD Frank Hartmann, MD » Ansprechpartner anzeigen Klinikum der Stadt Ludwigshafen am Rhein gGmbH 67063 Ludwigshafen (Rheinland-Pfalz) GermanyRekrutierend » Google-Maps Ansprechpartner: Peter Paschka, MD David Klank, MD » Ansprechpartner anzeigen Darmkrebszentrum am Universitätsklinikum Schleswig-Holstein, Campus Lübeck Ratzeburger Allee 160 23562 Lübeck DeutschlandRekrutierend » Google-Maps Ansprechpartner: Friedericke Wortmann, MD Hellen Sievert » Ansprechpartner anzeigen Klinikum Lüdenscheid 58515 Lüdenscheid (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Monika Schwalenberg, MD Lars Petersen, MD » Ansprechpartner anzeigen Universitätsklinikum Magdeburg 39120 Magdeburg (Sachsen-Anhalt) GermanyRekrutierend » Google-Maps Ansprechpartner: Martin Mikusko, MD Vanja Zeremski, MD » Ansprechpartner anzeigen Klinikum der Johannes Gutenberg Universität 55131 Mainz (Rheinland-Pfalz) GermanyRekrutierend » Google-Maps Ansprechpartner: Michael Kühn, MD Markus Radsak, MD » Ansprechpartner anzeigen Klniikum Hochsauerland GmbH 59872 Meschede (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Mohammad Wattad, MD Barbara Wenning, MD » Ansprechpartner anzeigen Johannes Wesling Klinikum Minden 32429 Minden (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Hans Joachim Tischler, MD Kai Wille, MD » Ansprechpartner anzeigen Klinikum rechts der Isar München 81675 München (Bayern) GermanyRekrutierend » Google-Maps Ansprechpartner: Katharina Götze, MD Katharina Nickel, MD » Ansprechpartner anzeigen Brustzentrum Sana Klinikum Offenbach Starkenburgring 66 63069 Offenbach am Main DeutschlandNoch nicht rekrutierend » Google-Maps Ansprechpartner: Ioannis Tsoukakis, MD Thomas Wehler, MD » Ansprechpartner anzeigen Ortenau Klinikum, Offenburg-Gengenbach 77654 Offenburg (Baden-Württemberg) GermanyRekrutierend » Google-Maps Ansprechpartner: Carsten Schwänen, MD Irmgard Dresel, MD » Ansprechpartner anzeigen Pius Hospital Oldenburg 26121 Oldenburg (Niedersachsen) GermanyRekrutierend » Google-Maps Ansprechpartner: Imme Conradi, MD Frank Griesinger, MD » Ansprechpartner anzeigen Klinikum Oldenburg gGmbH 26133 Oldenburg (Niedersachsen) GermanyRekrutierend » Google-Maps Ansprechpartner: Jochen Casper, MD Andrea Renzelmann, MD » Ansprechpartner anzeigen Gynäkologisches Krebszentrum Klinikum Passau Innstraße 76 94032 Passau DeutschlandRekrutierend » Google-Maps Ansprechpartner: Thomas Südhoff, MD Thorsten Nitsch, MD » Ansprechpartner anzeigen Pankreaskarzinomzentrum Universitätsklinikum Regensburg Franz-Josef-Strauß-Allee 11 93053 Regensburg DeutschlandRekrutierend » Google-Maps Ansprechpartner: Daniel Heudobler, MD Hendrik Poeck, MD » Ansprechpartner anzeigen Marienhaus Klinikum St. Elisabeth Saarlouis 66740 Saarlouis (Saarland) GermanyRekrutierend » Google-Maps Ansprechpartner: Alessandro Falgiatore, MD Katharina Gräber, MD » Ansprechpartner anzeigen Sande, Nordwest-Krankenhaus Sanderbusch 26453 Sande (Niedersachsen) GermanyRekrutierend » Google-Maps Ansprechpartner: Detlev Kohl, MD Jan-Eike Behrends, MD » Ansprechpartner anzeigen Brustzentrum Klinikum Stuttgart/Frauenklinik Kriegsbergstraße 60 70174 Stuttgart DeutschlandRekrutierend » Google-Maps Ansprechpartner: Jan Schleicher, MD Lisa Pospiech, MD » Ansprechpartner anzeigen Stuttgart, Diakonie-Klinikum 70176 Stuttgart (Baden-Württemberg) GermanyRekrutierend » Google-Maps Ansprechpartner: Jochen Greiner, MD Susanne Jung » Ansprechpartner anzeigen Darmzentrum Chiemgau am Klinikum Traunstein Cuno-Niggl-Straße 3 83278 Traunstein DeutschlandRekrutierend » Google-Maps Ansprechpartner: Elisabeth Dietl, MD Thomas Kubin, MD » Ansprechpartner anzeigen Darmzentrum Klinikum Mutterhaus der Borromäerinnen Trier Feldstraße 16 54290 Trier DeutschlandRekrutierend » Google-Maps Ansprechpartner: Rolf Mahlberg, MD Stefan Heidel, MD » Ansprechpartner anzeigen Darmzentrum am Krankenhaus der Barmherzigen Brüder Trier Nordallee 1 54292 Trier DeutschlandRekrutierend » Google-Maps Ansprechpartner: Heinz Kirchen, MD Monika Lankeshofer-Loch, MD » Ansprechpartner anzeigen Viszeralonkologisches Zentrum Universitätsklinikum Tübingen Hoppe-Seyler-Straße 3 72076 Tübingen DeutschlandRekrutierend » Google-Maps Ansprechpartner: Claudia Lengerke, MD Wichard Vogel, MD » Ansprechpartner anzeigen Leberkrebszentrum Universitätsklinikum Ulm Albert-Einstein-Allee 23 89081 Ulm DeutschlandRekrutierend » Google-Maps Ansprechpartner: Verena Gaidzik, MD Hartmut Döhner, MD » Ansprechpartner anzeigen Schwarzwald-Baar Klinikum Villingen- Schwenningen GmbH 78052 Villingen-Schwenningen (Baden-Württemberg) GermanyRekrutierend » Google-Maps Ansprechpartner: Paul Graf La Rosée, MD Martin Henkes, MD » Ansprechpartner anzeigen Helios Klinikum Wuppertal 42283 Wuppertal (Nordrhein-Westfalen) GermanyRekrutierend » Google-Maps Ansprechpartner: Silke Schostock, MD Blasius Liss, MD » Ansprechpartner anzeigen Medizinische Universität Graz 8036 Graz AustriaRekrutierend » Google-Maps Ansprechpartner: Armin Zebisch, MD » Ansprechpartner anzeigen Tirol Kliniken GmbH Innsbruck 6020 Innsbruck AustriaRekrutierend » Google-Maps Ansprechpartner: David Nachbaur, MD » Ansprechpartner anzeigen Ordensklinikum Linz GmbH, Elisabethinen 4020 Linz AustriaRekrutierend » Google-Maps Ansprechpartner: Sigrid Machherndl-Spandl, MD » Ansprechpartner anzeigen Feldkirch, Landeskrankenhaus 6830 Rankweil AustriaRekrutierend » Google-Maps Ansprechpartner: Bernd Hartmann, MD » Ansprechpartner anzeigen Landeskrankenhaus Salzburg 5020 Salzburg AustriaRekrutierend » Google-Maps Ansprechpartner: Richard Greil, MD » Ansprechpartner anzeigen Hanuschkrankenhaus Wien 1140 Wien AustriaRekrutierend » Google-Maps Ansprechpartner: Elisabeth Koller, MD » Ansprechpartner anzeigen Alle anzeigen
Brief Summary: The trial is a randomized, open-label phase III study comparing CPX-351 vs conventional intensive induction and consolidation chemotherapy in patients with newly diagnosed AML and intermediate- or adverse-risk genetics (according to 2017 ELN criteria), including AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML according to the World Health Organization (WHO) classification. Overall survival (OS) in the restricted set of de novo patients will be the primary endpoint.
Patient Inclusion Criteria: 1. Patients with newly diagnosed AML and intermediate- or adverse-risk genetics (according to 2017 ELN criteria [Appendix B]), including AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML according to the World Health Organization (WHO) classification 2. Age ≥ 18 years, no upper age limit 3. Patient considered eligible for intensive chemotherapy 4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at screening 5. Genetic assessment in AMLSG central laboratory 6. Adequate renal function as evidenced by serum creatinine ≤ 2.0 × ULN or creatinine clearance >40 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR) 7. Adequate hepatic function as evidenced by: - Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) unless considered due to Gilbert's disease, or leukemic involvement following approval by the Coordinating Investigator or Co-Coordinating Investigator - Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic involvement following approval by the Coordinating Investigator or Co-Coordinating Investigator 8. No prior chemotherapy for acute leukemia except hydroxyurea for up to 7 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell [WBC] counts >30x109/l); prior treatment of myelo-dysplastic syndrome with hypomethylating agents is allowed 9. Non-pregnant and non-nursing women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to randomization ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or bilateral oophorectomy or who has had menses at any time in the preceding 24 consecutive months) 10. Female patients of childbearing potential must agree to avoid getting pregnant while on therapy and for 27 weeks after the last dose of study drug 11. Women of childbearing potential must either commit to continued abstinence from heterosexual intercourse or apply one highly effective method of birth control (such as IUD, bilateral tubal ligation, or partner's vasectomy) in combination with one acceptable method of birth control at the same time (such as hormonal contraception or the male partner has to use a latex condom coated with spermicide lubricant or combined with spermicide gel or foam) while on therapy and for 27 weeks after the last dose of study drug. Hormonal contraception is only a highly effective method of birth control in case of combined (estrogen and progestogen containing) associated with inhibition of ovulation or progestogen-only hormonal contraception associated with inhibition of ovulation is used 12. Men must use a latex condom coated with a spermicide lubricant or combined with spermicide gel or foam during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 6 months after the last dose of study drug). In addition, their female partners of childbearing potential have to use a highly effective method of birth control 13. Able to understand and willing to sign an informed consent form (ICF) Patient Exclusion Criteria: 1. AML with favorable-risk genetics according to 2017 ELN criteria [Appendix B]: - AML with t(8;21)(q22;q22.1), RUNX1-RUNX1T1 - AML with inv(16)(p13.1q22)/t(16;16)(p13.1;q22), CBFB-MYH11 - AML with mutated NPM1 without FLT3-ITD or with FLT3-ITDlow - AML with biallelic CEBPA mutation 2. AML with FLT3 mutation as assessed by DNA fragment analysis PCR for FLT3-ITD and FLT3-TKD mutation. Positivity is defined as a FLT3-ITD or FLT3-TKD / FLT3-WT ratio of ≥ 0.05 (5%). 3. Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); PML-RARA; or one of the other pathognomonic variant chromosomal translocations/ fusion genes 4. AML with BCR-ABL1 5. Prior treatment of myelodysplastic syndrome (MDS) with intensive chemotherapy or bone marrow transplant with a curative intent 6. Significant active cardiac disease within 6 months prior to the start of study treatment, including New York Heart Association (NYHA) class III or IV congestive heart failure; myocardial infarction, unstable angina and/or stroke; severe cardiac arrhythmias, or left ventricular ejection fraction (LVEF) <50% by ultrasound obtained within 28 days prior to the start of study treatment 7. Severe obstructive or restrictive ventilation disorder 8. Uncontrolled infection 9. Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is only required, if there is a clinical suspicion of CNS involvement by leukemia during screening 10. Evidence of active hepatitis B or C infection or known Human Immunodeficiency Virus (HIV) infection 11. Patients with a "currently active" second malignancy. Patients are not considered to have a currently active malignancy, if they have completed therapy and are considered by their physician to be at < 30% risk of relapse within one year. However, subjects with the following history/concurrent conditions are allowed: - Basal or squamous cell carcinoma of the skin - Carcinoma in situ of the cervix - Carcinoma in situ of the breast - Incidental histologic finding of prostate cancer 12. Severe neurological or psychiatric disorder interfering with ability to give an informed consent 13. No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation 14. No consent for biobanking of patient's biological specimens 15. Current participation in any other interventional clinical study within 30 days before the first administration of the investigational product or at any time during the study 16. Patients with prior cumulative anthracycline exposure of daunorubicin (or equivalent) can be included but the maximum of daunorubicin (or equivalent) dose of 550 mg/m2 must not be exceeded. Anthracycline-based therapy should be avoided until exposure to the previous cardiotoxic agents is negligible. If this is not possible, the patient's cardiac function should be carefully monitored and an absolute cumulative dose of 400 mg/m² in adults can be exceeded only with great caution. In patients who received radiation therapy to the mediastinum the maximum of daunorubicin (or equivalent) dose of 400 mg/m2 must not be exceeded. 17. Known or suspected hypersensitivity to cytarabine, daunorubicin or liposomal products and/or any excipients 18. History of Wilson's disease or other copper-metabolism disorder 19. Receipt of live, attenuated vaccine within 30 days prior to the study inclusion (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and until 6 months after the therapy).
Primary outcome: 1. Overall survival (OS) in the restricted set of de novo patients (Time Frame - 2 years)Secondary outcome: 1. Overall survival (OS) in the extended set of patients (Time Frame - 2 years) 2. Event-free survival (EFS) with CRi considered as response to induction therapy in both, the restricted set of de novo patients and the extended set of patients (Time Frame - 2 years) 3. Event-free survival (EFS) with CRi considered as failure of induction therapy in the restricted set of de novo patients (Time Frame - 2 years) 4. Rate of objective response in the restricted set of de novo patients (Time Frame - 2 months):complete remission [CR], CR with incomplete hematologic recovery [CRi], CRi without measurable residual disease [CRiMRD-], CR without measurable residual disease [CRMRD-])
Active Comparator: Standard arm Experimental: Investigational arm
Cytarabine:Induction therapy: 200 mg/m2 i.v. (continuously) d1-7
Consolidation therapy:
Patients age 18-60 years
o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3
Patients age >60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3 Daunorubicin:Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3 CPX-351:Induction 1:
o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3,5
Induction 2:
o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3
Consolidation therapy:
o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine [65 U/m²] i.v. (90 min) d1,3
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (* ) gekennzeichneten Angaben müssen eingetragen werden!